医疗器械及医药股普遍逆市捱沽 微创(00853.HK)爱康(01789.HK)挫逾一成
医疗器械及医药股今天逆市下跌,尤其是微创医疗(00853.HK)三连跌,今天股价一举跌破20天、10天及50天线(31.5-32.6元),最低见29.05元,现造29.25元,续挫10.6%,成交急增至2,249万股,涉资6.74亿元。爱康医疗(01789.HK)失守20天、10天及100天线(20.8元、21.8元及22.2元),最低见20.05元,现造20.3元,急吐11%,成交增至609万股。
海吉亚医疗(06078.HK)四连跌兼失守10天线(48.7元),最低见46.3元,现造46.4元,续跌6.1%。康基医疗(09997.HK)反覆吐5.9%,报21.65元,股价失守20天及10天线(21.75元及22.2元)。
复生医药(02196.HK)、蓝筹药明生物(02269.HK)/石药集团(01093.HK)、药明康德(02359.HK)、联邦制药(03933.HK)及威高股份(01066.HK)也跌逾2%-4%,後者沽压最大,股价失守20天线(15.85元),最低见14.72元,创四个月低,现造15.22元,跌4.5%。
国家组织高值医用耗材联合采购办公室上周五(16日)正式发布《国家组织冠脉支架集中带量采购文件》,是迄今为止第一个在国家层面进行的高值耗材带量采购项目,显示在药品国家集采常态化後,医疗器械市场也迎来集采,产品价格有望大幅下调,相关公司业绩或受到影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.